| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/21/2023 | 587.02% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 09/19/2023 | 587.02% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 08/10/2023 | 587.02% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 06/28/2023 | 587.02% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 06/21/2023 | 587.02% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 05/15/2023 | 587.02% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 04/21/2023 | 587.02% | HC Wainwright & Co. | $20 → $9 | Maintains | Buy |
| 11/08/2022 | 587.02% | Canaccord Genuity | → $9 | Initiates Coverage On | → Buy |
| 09/02/2021 | 52.67% | Cantor Fitzgerald | → $2 | Initiates Coverage On | → Overweight |
| 05/14/2021 | 52.67% | HC Wainwright & Co. | $1.5 → $2 | Maintains | Buy |
| 05/04/2020 | 14.5% | HC Wainwright & Co. | $2 → $1.5 | Reiterates | → Buy |
| 09/06/2019 | 52.67% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
| 03/19/2019 | 14.5% | Wells Fargo | $6 → $1.5 | Maintains | Market Perform |
What is the target price for Regulus Therapeutics (RGLS)?
The latest price target for Regulus Therapeutics (NASDAQ: RGLS) was reported by HC Wainwright & Co. on September 21, 2023. The analyst firm set a price target for $9.00 expecting RGLS to rise to within 12 months (a possible 587.02% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Regulus Therapeutics (RGLS)?
The latest analyst rating for Regulus Therapeutics (NASDAQ: RGLS) was provided by HC Wainwright & Co., and Regulus Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Regulus Therapeutics (RGLS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regulus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regulus Therapeutics was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.
Is the Analyst Rating Regulus Therapeutics (RGLS) correct?
While ratings are subjective and will change, the latest Regulus Therapeutics (RGLS) rating was a reiterated with a price target of $0.00 to $9.00. The current price Regulus Therapeutics (RGLS) is trading at is $1.31, which is within the analyst's predicted range.